Burley Brewton was able to count on a new advancement in targeted therapy after he was diagnosed with prostate cancer, the ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, ...

The MHRA has approved tisotumab vedotin for adults with recurrent or metastatic cervical cancer, offering a new option after ...

Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...

Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...